Tirzepatide vs. Semaglutide: Weight Loss, Side Effects, Cost, and the Details That Actually Matter
For compounded tirzepatide complete guide, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
A colleague of mine in family medicine outside Denver told me about a patient visit last fall that perfectly captures the state of obesity pharmacotherapy right now. A 48-year-old woman walked in with printouts from three different websites, a screenshot of a TikTok comparing Zepbound and Wegovy, and a quote from a compounding pharmacy. She wanted to know which drug was “the better one.” My colleague’s answer: “Better for what, exactly?” That question, not the answer, is the real starting point.
So here is the direct answer. Tirzepatide produces greater mean weight loss than semaglutide in the head-to-head data we have. SURMOUNT-1 reported up to 20.9% mean body weight reduction at 15 mg tirzepatide over 72 weeks (Jastreboff et al., NEJM 2022). STEP-1 reported up to 14.9% with semaglutide 2.4 mg over 68 weeks (Wilding et al., NEJM 2021). But mean weight loss in a trial population is not the same thing as what happens to a specific person sitting in your exam room. The rest of this piece is about the specifics that bridge that gap.
Why the Dual-Receptor Thing Actually Matters
Semaglutide targets the GLP-1 receptor. Tirzepatide hits both GLP-1 and GIP receptors. For a while the obvious question was whether that second receptor target was doing real clinical work or was mostly a pharmacology talking point. SURMOUNT-5, the head-to-head trial, suggests it does matter: tirzepatide produced greater mean weight loss than semaglutide over 72 weeks.
The boring truth is we still don’t fully understand the GIP receptor’s independent contribution to weight loss. GIP signaling is involved in fat metabolism and insulin secretion, and the prevailing hypothesis is that dual agonism produces additive or synergistic metabolic effects. But teasing apart which receptor is responsible for which clinical outcome in a dual-agonist molecule is not straightforward, and the mechanistic picture is still being filled in.
What clinicians can say with confidence: the clinical outcomes data favors tirzepatide on weight loss magnitude. For individual patients, though, the gap between the two molecules may be smaller or larger than trial averages suggest, and tolerability sometimes ends up being the deciding factor.
The Side Effect Profile Is More Similar Than Different
GI symptoms dominate both drugs because GLP-1 receptor activity is the primary driver of nausea, diarrhea, constipation, and vomiting. Think of it like two cars with the same engine but different transmissions. The ride quality differs, but the noise is coming from the same place.
In trial populations, tirzepatide nausea runs 30 to 45%, diarrhea 15 to 23%, constipation 10 to 17%, vomiting 8 to 13%. Reflux is probably underreported at 7 to 12%. Most of these symptoms cluster in the first 4 to 8 weeks and around dose escalations, then attenuate within 2 to 3 weeks at a stable dose.
| Symptom | Reported Frequency | Typical Timing | Management | |—|—|—|—| | Nausea | 30 to 45% | First 4 to 8 weeks, worse at dose increases | Smaller meals, lower fat intake, antiemetic if persistent | | Diarrhea | 15 to 23% | Variable | Hydration, electrolyte review, BRAT-style meals briefly | | Constipation | 10 to 17% | Often after GI slowing kicks in | Fiber 25 to 35 g daily, hydration, magnesium if cleared | | Vomiting | 8 to 13% | First weeks; escalation periods | Hold dose, consult prescriber if persistent | | Reflux | 7 to 12% | Throughout therapy | No eating within 3 hours of bedtime, head-of-bed elevation | | Fatigue | Variable | First weeks | Usually self-resolves; check ferritin, B12, thyroid if persistent |
Serious labeled risks include pancreatitis, gallbladder disease, severe hypoglycemia (especially when combined with insulin or sulfonylureas), kidney injury from dehydration, and the boxed warning for medullary thyroid carcinoma from rodent studies.
Where this falls apart as a clean comparison: some patients who can’t tolerate semaglutide do fine on tirzepatide, and vice versa. The reasons are not always obvious. It may be receptor selectivity differences, pharmacokinetic variation, or just the idiosyncrasies of individual GI tracts. Clinically, switching is a legitimate tool when one molecule is poorly tolerated.
Dosing: The Titration Ladder
Standard tirzepatide dosing starts at 2.5 mg weekly for four weeks. This is the tolerance phase. Expecting meaningful weight loss here is like expecting a car to perform at highway speed in first gear.
| Phase | Typical Dose | Duration | Notes | |—|—|—|—| | Initiation | 2.5 mg weekly | Weeks 1 to 4 | GI tolerance building, not weight loss | | Step 1 | 5 mg weekly | Weeks 5 to 8 | First real therapeutic dose for most patients | | Step 2 | 7.5 mg weekly | Weeks 9 to 12 | Some protocols hold here if response is adequate | | Step 3 | 10 mg weekly | Weeks 13 to 16 | Common long-term maintenance tier | | Step 4 | 12.5 mg weekly | Weeks 17 to 20 | For patients with attenuating response | | Step 5 | 15 mg weekly | Week 21 onward | Maximum labeled dose; not everyone needs it |
Not every patient needs to reach 15 mg. Many stabilize at 5 to 10 mg once they hit their goal weight, with the dose chosen to balance ongoing benefit against side effects and cost.
One practical note: compounded preparations sometimes allow intermediate doses (6.25 mg, 8.75 mg) that branded autoinjectors don’t offer. For patients who hit a wall at one dose but overshoot on the next branded step, that flexibility can be genuinely useful.
Branded vs. Compounded: What’s Different and What Isn’t
The active ingredient, tirzepatide, is the same molecule in branded and compounded preparations. The differences are manufacturing oversight, regulatory pathway, packaging, and price.
Branded Zepbound and Mounjaro are FDA-approved finished drugs manufactured by Eli Lilly under cGMP standards, with established labeling and post-marketing surveillance. Compounded preparations come from 503A pharmacies (patient-specific prescriptions) or 503B outsourcing facilities (cGMP-inspected, may produce office stock). Compounded preparations are not FDA-evaluated for safety, efficacy, or quality in the way branded products are. The regulatory framework relies on state pharmacy board oversight, federal 503A/503B requirements, and prescriber clinical judgment.
If you’re considering a compounded option, look at three things: pharmacy credentialing (state licensure, accreditation if applicable), clinical oversight (a real clinician evaluation, not a checkbox form), and pricing transparency.
For a deeper side-by-side reference on dosing, monitoring, and the regulatory context around both molecules, see https://formblends.com/articles/glp1-hub/compounded-tirzepatide-complete-guide. It organizes most of what patients need when comparing options in one place.
Switching Between the Two (and When Not To)
Switching from semaglutide to tirzepatide because of a plateau: typically start tirzepatide at 2.5 mg weekly the week after the last semaglutide dose. Do not dose-match. The molecules are different; the numbers don’t translate.
Switching from tirzepatide to semaglutide for cost or insurance reasons: start semaglutide at 0.25 mg weekly. Expect a tolerance acclimation period similar to starting from scratch.
Switching because of side effects: address the side effect first. Slow the titration, adjust diet, hold at a lower dose. If the problem is GLP-1 receptor-mediated (and many GI symptoms are), switching to the other GLP-1-active molecule may not resolve it.
Switching is not appropriate during pregnancy planning or for patients with absolute contraindications to both molecules. And patients should not do this independently. The transition involves dose pacing, monitoring, and managing any gap period. It’s a clinical decision.
Baseline Labs and Monitoring
A reasonable baseline panel before starting tirzepatide:
- Comprehensive metabolic panel (CMP) for liver and kidney function
- HbA1c and fasting glucose
- Lipid panel
- TSH for thyroid baseline
- Lipase if there’s any personal history of pancreatitis
- CBC
Repeat at 12 to 16 weeks, then roughly every 6 months once stable. Severe abdominal pain that radiates to the back warrants immediate clinician contact to rule out pancreatitis. This isn’t a “watch and wait” symptom.
Routine clinical follow-up every 12 to 16 weeks during active titration and every 6 months at maintenance is a reasonable cadence.
When to Involve a Clinician (Before and During Therapy)
Before starting therapy, a clinician conversation is essential if you have: personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, history of pancreatitis, severe gastroparesis, severe hepatic impairment, current pregnancy or active pregnancy planning, or current use of insulin or sulfonylureas without diabetes management oversight.
During therapy, contact a clinician for: severe persistent abdominal pain (especially radiating to the back), signs of dehydration from vomiting or diarrhea, vision changes (particularly in diabetic patients), severe persistent reflux, signs of allergic reaction, or any symptom that feels markedly outside the routine titration experience.
Frequently Asked Questions
Which drug produces more weight loss?
SURMOUNT-5 head-to-head data reported greater mean weight loss with tirzepatide than semaglutide over 72 weeks. SURMOUNT-1 reported up to 20.9% mean loss at 15 mg tirzepatide. STEP-1 reported up to 14.9% with semaglutide 2.4 mg. Individual responses vary considerably around those means.
Which is better tolerated?
GI side effect profiles are broadly similar since both drugs work through GLP-1 receptor activity. Some patients tolerate one better than the other for reasons that aren’t always predictable. Clinical switching is a reasonable strategy when tolerance is the issue.
What’s the dosing difference?
Tirzepatide doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. Semaglutide (Wegovy) doses: 0.25, 0.5, 1.0, 1.7, and 2.4 mg weekly. The numbers are not comparable across products because the molecules are different.
Which is cheaper?
Compounded versions of either are typically less expensive than branded. Branded Zepbound and Wegovy retail prices sit in similar ranges, though manufacturer self-pay programs vary. Cost often becomes the practical deciding factor for long-term use.
Can I take both at the same time?
Combining GLP-1 agonists is not standard clinical practice and is not supported by trial data. Don’t do this.
Which works faster?
Onset of appetite suppression is similar for both, typically within the first 2 to 4 weeks. Weight loss accelerates as the dose climbs during titration.
Do I need to stay on it forever?
Weight regain after discontinuation is well-documented for both molecules. The current evidence supports long-term or indefinite use for weight maintenance, though this is an evolving area of research and an important conversation to have with your prescriber.
Important regulatory note. Compounded tirzepatide is not FDA-approved. It is prepared by licensed 503A or 503B pharmacies for individual patients based on a prescriber’s clinical judgment. Compounded preparations are not evaluated by the FDA for safety, efficacy, or quality the way branded products are. Research suggests outcomes vary between patients, and any decision to begin, modify, or discontinue therapy should occur in coordination with a licensed clinician who can review your medical history, current medications, and laboratory values.
